Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 6Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

Sunitinib 86Sorafenib 60Everolimus 47pazopanib 46Bevacizumab 46Nivolumab 44pembrolizumab 37aldesleukin 29Interferon-alpha 26Axitinib 24temsirolimus 23cabozantinib 20Interleukin-2 19Ipilimumab 16Interferon alpha-2 15Cyclophosphamide 15fludarabine phosphate 14Gemcitabine 14Peripheral Blood Stem Cell Transplantation 11Sirolimus 10Paclitaxel 10Erlotinib Hydrochloride 10avelumab 8Radiosurgery 8Docetaxel 8Cyclosporine 8Capecitabine 8tremelimumab 7lenvatinib 7Mycophenolic Acid 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Renal Cell × fluzoparib × Clear all
NCT04535687 2023-06-13

Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Completed
1 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡